Liliana Moreira-Costa

Dr. Liliana Moreira-Costa

Cardiovascular R&D Unit (UnIC), Department of Surgery and Physiology, Faculty of Medicine of University of Porto, Porto, Portugal
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Proteomes
Verified
Journal Article
Open access
PDF file
Liliana Moreira-CostaLiliana Moreira-Costa
Liliana Moreira-Costa
ABAntonio Barros
Antonio Barros
ALAndré Lourenço
André Lourenço
AMAdelino Leite Moreira
Adelino Leite Moreira
RNRita Nogueira-Ferreira
Rita Nogueira-Ferreira
Rui VitorinoRui Vitorino
Rui Vitorino
Cardiovascular diseases (CVDs) are widely recognized as the leading cause of mortality worldwide. Despite the advances in clinical management over the past decades, the underlying pathological mechanisms remain largely unknown. Exosomes have drawn the attention of researchers for their relevance in intercellular communication under both physiological and pathological conditions. These vesicles are suggested as complementary prospective biomarkers of CVDs; however, the role of exosomes in CVDs is still not fully elucidated. Here, we performed a literature search on exosomal biogenesis, characteristics, and functions, as well as the different available exosomal isolation techniques. Moreover, aiming to give new insights into the interaction between exosomes and CVDs, network analysis on the role of exosome-derived mediators in coronary artery disease (CAD) and heart failure (HF) was also performed to incorporate the different sources of information. The upregulated exosomal miRNAs miR-133a, miR-208a, miR-1, miR-499-5p, and miR-30a were described for the early diagnosis of acute myocardial infarction, while the exosome-derived miR-192, miR-194, miR-146a, and miR-92b-5p were considered as potential biomarkers for HF development. In CAD patients, upregulated exosomal proteins, including fibrinogen beta/gamma chain, inter-alpha-trypsin inhibitor heavy chain, and alpha-1 antichymotrypsin, were assessed as putative protein biomarkers. From downregulated proteins in CAD patients, albumin, clusterin, and vitamin D-binding protein were considered relevant to assess prognosis. The Vesiclepedia database included miR-133a of exosomal origin upregulated in patients with CAD and the exosomal miR-192, miR-194, and miR-146a upregulated in patients with HF. Additionally, Vesiclepedia included 5 upregulated and 13 downregulated exosomal proteins in patients in CAD. The non-included miRNAs and proteins have not yet been identified in exosomes and can be proposed for further research. This report highlights the need for further studies focusing on the identification and validation of miRNAs and proteins of exosomal origin as biomarkers of CAD and HF, which will enable, using exosomal biomarkers, the guiding of diagnosis/prognosis in CVDs.

30 July 2021 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
SLSara Leite
Sara Leite
Liliana Moreira-CostaLiliana Moreira-Costa
Liliana Moreira-Costa
RCRui Cerqueira
Rui Cerqueira
CSCláudia Sousa-Mendes
Cláudia Sousa-Mendes
AAAntónio Angélico-Gonçalves
António Angélico-Gonçalves
ALAndré P. Lourenço
André P. Lourenço
Although decreased protein kinase G (PKG) activity was proposed as potential therapeutic target in heart failure with preserved ejection fraction (HFpEF), randomized clinical trials (RCTs) with type-5 phosphodiesterase inhibitors (PDE5i) showed neutral results. Whether specific subgroups of HFpEF patients may benefit from PDE5i remains to be defined. Our aim was to test chronic sildenafil therapy in the young male ZSF1 obese rat model of HFpEF with severe hypertension and metabolic syndrome. Sixteen-week-old ZSF1 obese rats were randomly assigned to receive sildenafil 100 mg·Kg−1·d−1 dissolved in drinking water (ZSF1 Ob SIL, n = 8), or placebo (ZSF1 Ob PL, n = 8). A group of Wistar-Kyoto rats served as control (WKY, n = 8). Four weeks later animals underwent effort tests, glucose metabolism studies, hemodynamic evaluation, and samples were collected for aortic ring preparation, left ventricular (LV) myocardial adenosine triphosphate (ATP) quantification, immunoblotting and histology. ZSF1 Ob PL rats showed systemic hypertension, aortic stiffening, impaired LV relaxation and increased LV stiffness, with preserved ejection fraction and cardiac index. Their endurance capacity was decreased as assessed by maximum workload and peak oxygen consumption (V˙O2) and respiratory quotient were increased, denoting more reliance on anaerobic metabolism. Additionally, ATP levels were decreased. Chronic sildenafil treatment attenuated hypertension and decreased LV stiffness, modestly enhancing effort tolerance with a concomitant increase in peak, ATP levels and VASP phosphorylation. Chronic sildenafil therapy in this model of HFpEF of the young male with extensive and poorly controlled comorbidities has beneficial cardiovascular effects which support RCTs in HFpEF patient subgroups with similar features.

23 January 2024 in European Journal of Pharmacology
Verified
Journal Article
Open access
Liliana Moreira-CostaLiliana Moreira-Costa
Liliana Moreira-Costa
MTMarta Tavares-Silva
Marta Tavares-Silva
JAJoão Almeida-Coelho
João Almeida-Coelho
AGAlexandre Gonçalves
Alexandre Gonçalves
FTFábio Trindade
Fábio Trindade
ALAndré Lourenço
André Lourenço
Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterized by impaired cardiovascular reserve in which therapeutic options are scarce. Our aim was to evaluate the inodilator levosimendan in the ZSF1 obese rat model of HFpEF. Twenty-week-old male Wistar-Kyoto (WKY), ZSF1 lean (ZSF1 Ln) and ZSF1 obese rats chronically treated for 6-weeks with either levosimendan (1 mg/kg/day, ZSF1 Ob + Levo) or vehicle (ZSF1 Ob + Veh) underwent peak-effort testing, pressure-volume (PV) haemodynamic evaluation and echocardiography (n = 7 each). Samples were collected for histology and western blotting. In obese rats, skinned and intact left ventricular (LV) cardiomyocytes underwent in vitro functional evaluation. Seven additional ZSF1 obese rats underwent PV evaluation to assess acute levosimendan effects (10 μg/kg + 0.1 μg/kg/min). ZSF1 Ob + Veh presented all hallmarks of HFpEF, namely effort intolerance, elevated end-diastolic pressures and reduced diastolic compliance as well as increased LV mass and left atrial area, cardiomyocyte hypertrophy and increased interstitial fibrosis. Levosimendan decreased systemic arterial pressures, raised cardiac index, and enhanced LV relaxation and diastolic compliance in both acute and chronic experiments. ZSF1 Ob + Levo showed pronounced attenuation of hypertrophy and interstitial fibrosis alongside increased effort tolerance (endured workload raised 38 %) and maximum O2 consumption. Skinned cardiomyocytes from ZSF 1 Ob + Levo showed a downward shift in sarcomere length-passive tension relationship and intact cardiomyocytes showed decreased diastolic Ca2+ levels and enhanced Ca2+ sensitivity. On molecular grounds, levosimendan enhanced phosphorylation of phospholamban and mammalian target of rapamycin. The observed effects encourage future clinical trials with levosimendan in a broad population of HFpEF patients.

9 April 2025 in Materials Today Bio
Verified
Journal Article
Open access
LMLuís M. Monteiro
Luís M. Monteiro
PGPedro J. Gouveia
Pedro J. Gouveia
FVFrancisco Vasques-Nóvoa
Francisco Vasques-Nóvoa
SRSusana Rosa
Susana Rosa
IBIfigeneia Bardi
Ifigeneia Bardi
DNDiana S Nascimento
Diana S Nascimento
Ischemic heart disease is the leading cause of death worldwide. Several approaches have been explored to restore cardiac function, however few investigated new strategies to improve electrical functional recovery. Herein, we have investigated the impact of piezoelectric patches (Piezo patches), capable of generating electric charges upon mechanical deformation, on rat cardiac slices, healthy and ischemic hearts (ex vivo), on infarcted mice (in vivo) and on healthy and infarcted pigs (in vivo). Piezo patches did not preclude cardiac slice contractility, while compared with electrically inert control patches. In addition, Piezo patches showed an adequate safety profile in a working heart model as no electrophysiologic alterations were detected in healthy hearts. Epicardial implantation of Piezo patches in acutely infarcted mice hearts significantly improved myocardial electrical integrity without disturbing systolic function. Moreover, Piezo patches partially prevented ischemia-related adverse cardiac remodeling, reducing left ventricular chamber dilatation and compensatory hypertrophy. Coherently, Piezo patch-implanted hearts revealed downregulation of genes associated with extracellular matrix remodeling. Importantly, in vivo implantation of Piezo patches in porcine hearts revealed to be electrically safe as no major effects in its electrophysiology were detected. Overall, the results presented here endorse Piezo patches as a promising therapeutic strategy to improve post-myocardial infarction structural and electrical remodeling.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
Liliana Moreira-CostaLiliana Moreira-Costa
Liliana Moreira-Costa
RARui Adão
Rui Adão
IMIsabel Miranda
Isabel Miranda
RCRui Cerqueira
Rui Cerqueira
FPFrederic Perros
Frederic Perros
PMPedro Mendes-Ferreira
Pedro Mendes-Ferreira
Introduction: There is a need for large animal models of pulmonary hypertension (PH) that allow application of new therapies in a translational setting. Aims and objectives: To develop a simple large animal model of PH with right ventricular (RV) failure, mimicking chronic thromboembolic PH (CTEPH). Previous attempts have used short suture segments, microspheres and pharmacological interventions. Methods: 2-month old pigs were used. Right heart catheterization (RHC) was performed, and a sheath was advanced into the left or right PA and a pressure transducer was placed at its tip. Long silk sutures were injected into the selected PA, while continuously recording pressures. Embolization was stopped when mean PAP≥40 mmHg, or occlusion of the selected branch. The procedure was repeated for 3 weeks, with a 3-6 weeks follow-up. Echocardiographic and hemodynamic analysis was performed and samples were collected. Results: Embolization led to an increase in PA pressure, which was attenuated at re-intervention, but aggravated during follow-up. A significant portion of both right and left lower lobes were obstructed. RHC showed severe PH development (mPAP = 49 +/- 5 mmHg). Significant RV hypertrophy and failure (lower TAPSE and EF) were observed. Adverse remodelling markers (MYH7/MYH6, NPPB and TNFA) were up-regulated, while ATP2A2 was down-regulated. Isolated skinned RV cardiomyocyte analysis showed significantly increased passive stiffness. Vascular remodelling was observed in distal arteries of the right upper lung lobe subjected to high flow/high shear stress. Conclusions: We created a model of chronic PH by injecting long sutures into the pulmonary circulation, without the need for additional hits.